MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apm.12625

Медицинская библиотека · APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2016

HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer.

Aarenstrup Karlsen Mona, Høgdall Claus, Nedergaard Lotte, Philipsen Prahm Kira, Schou Karlsen Nikoline Marie, Weng Ekmann-Gade Anne, Henrichsen Schnack Tine, Svenstrup Poulsen Tim, Jarle Christensen Ib, Høgdall Estrid

СтатьяПеревод пока не подготовлен

Аннотация

The aim of this study was to investigate the value of serum human epididymis protein 4 (HE4) and HE4 tissue protein expression to predict tumor resistance to adjuvant chemotherapy, progression-free survival (PFS), and overall survival in patients with epithelial ovarian cancer (EOC). Consecutive inclusion of 198 patients diagnosed with EOC was conducted. Blood samples were collected prior to surgery and tissue samples during surgery. Patient data were registered prospectively in the Danish Gynecologic Cancer Database. The association between serum HE4 and HE4 tissue protein expression, resistance to adjuvant chemotherapy, PFS, and overall survival were analyzed in univariate analyses and in multivariate analyses adjusted for age, performance score, surgical outcome, stage, grade, and histological subtype. Serum HE4 levels predicted chemotherapy resistance, PFS, and overall survival correlated significantly (p < 0.001) in the univariate analyses; but after adjustment in a multivariate model, serum HE4 was insignificant, except in a subgroup analysis of postmenopausal women, where serum HE4 significantly predicted resistance to chemotherapy and progression-free survival. HE4 tissue protein expression predicted PFS (p = 0.022) and overall survival (p = 0.047) in the univariate analysis, while HE4 tissue protein expression failed to predict these outcomes in the adjusted multivariate analyses. Serum HE4 or HE4 tissue protein expression are not independent factors of chemotherapy resistance or survival in patients with EOC, but serum HE4 might predict chemotherapy resistance and PFS in postmenopausal women.

Для цитирования: Aarenstrup Karlsen Mona, Høgdall Claus, Nedergaard Lotte, Philipsen Prahm Kira, Schou Karlsen Nikoline Marie, Weng Ekmann-Gade Anne, Henrichsen Schnack Tine, Svenstrup Poulsen Tim, Jarle Christensen Ib, Høgdall Estrid. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer.. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2016. DOI: 10.1111/apm.12625.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.